Which research results from the American Society for Radiation Oncology’s 2019 annual meeting are the most interesting or clinically relevant? The staff of Cleveland Clinic Cancer Center’s Department of Radiation Oncology picks their Top 10.
An automated software program developed by Cleveland Clinic to prospectively screen radiation treatment planning parameters for common errors is highly effective at reducing mistakes, but requires updating to remain optimal as radiotherapy equipment and workflows change.
A new study demonstrates that simultaneous targeting of two critical enzymes in the pyrimidine synthesis pathway inhibits self-renewal and tumorigenesis of glioblastoma stem cells, suggesting a way forward in treating the aggressive brain cancer.
Stereotactic body radiation therapy (SBRT) well tolerated in pediatric patients with metastatic disease. Pediatric radiologist Erin Murphy, MD, explains the potential benefits of this targeted, high-dose radiation therapy.
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services Policy
A new study confirms that preoperative pelvic radiation, with or without concurrent chemotherapy, is safe and effective in IBD patients with locally advanced rectal cancer.
By incorporating prostate-specific antigen kinetics into a widely used prostate cancer nomogram, Cleveland Clinic researchers are getting a more precise look at potential outcomes after salvage radiotherapy.
Cleveland Clinic Cancer Center researchers will take part in the following oral and poster presentations during the 2019 ASTRO Annual Meeting Sept. 15-18 at Chicago’s McCormick Place West.
Cleveland Clinic researchers have trained an advanced computer network to find subtle radiation sensitivity features in the CT scans of individual lung cancer patients that can predict the likelihood of successful radiotherapy outcomes. The network can generate a personalized radiation dose plan that reduces the probability of treatment failure to less than 5%.